[Form 4/A] Viemed Healthcare, Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Michael Moore, President of Viemed Healthcare (VMD), filed an amended Form 4 to correct his reported holdings after a sale. The amendment records a disposal of 8,948 common shares tied to the market closing price on 01/29/2025 with a per-share value shown as $8.28. The corrected post-transaction beneficial ownership is 176,433 shares, amended from an earlier reported 177,433 shares. The filing states the original error affected a prior Form 4 filed July 1 and that subsequent filings will reflect the corrected balance.

Positive

• Amendment corrects prior reporting and clarifies the accurate beneficial ownership (176,433 shares).
• Transaction details disclosed: the sale amount (8,948 shares) and per-share value ($8.28) are reported.

Negative

• Officer disposed of 8,948 shares, reducing beneficial ownership.
• Original filing contained an incorrect ending balance (177,433 reported, corrected to 176,433), indicating a prior reporting error.

Insights

Financial Analyst

TL;DR: Routine insider sale and a corrected ownership balance; transaction disclosed but not materially transformative.

The Form 4/A reports a non-derivative disposal of 8,948 common shares at an indicated price of $8.28 (market close on 01/29/2025) and corrects the ending beneficial ownership to 176,433 shares. For investors, this is a transparent disclosure of an officer sale and an administrative correction to prior reporting. Absent additional context about intent or larger changes in holdings, the item is informational rather than a material operational or financial development.

Corporate Governance Expert

TL;DR: Amendment fixes a reporting error and highlights the need for accurate insider reporting controls.

The amendment clarifies a previously misstated ending balance (originally 177,433 shares, corrected to 176,433) and notes the error impacted a July 1 Form 4. This underscores a recordkeeping or filing accuracy issue rather than a substantive corporate governance change. The filing itself demonstrates corrective action; regulators and investors will note the correction but the filing contains no indication of disciplinary or legal actions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Moore Michael

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/31/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/29/2025		D		8,948	D	$8.28(1)	176,433(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Per share value is based on the market closing price of the common shares for January 29, 2025.

2. This amendment is being filed to correct an error in the number of securities beneficially owned following the reported transaction. The ending balance originally reported was 177,433 shares. The correct number is 176,433 shares. This error also impacted the Reporting Person's Form 4 filing made on July 1, 2025. Subsequent Form 4 filings will reflect the corrected balance.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael Moore report on the Form 4/A for Viemed (VMD)?

The Form 4/A reports a non-derivative disposal of 8,948 common shares with an indicated per-share value of $8.28, and corrects the reporting person's post-transaction beneficial ownership to 176,433 shares.

How many Viemed (VMD) shares did the reporting person own after the transaction?

The corrected beneficial ownership after the reported transaction is 176,433 shares (originally misstated as 177,433).

What price per share is shown for the transaction on the Form 4/A?

The per-share value shown on the form is $8.28, based on the market closing price on 01/29/2025.

Does the filing report any derivative transactions for Viemed (VMD)?

No. Table II (derivative securities) contains no entries; the filing reports only a non-derivative sale in Table I.

Why was this Form 4 amended?

The amendment corrects an error in the number of securities beneficially owned following the reported transaction and notes the error affected a prior Form 4 filed on July 1; subsequent filings will reflect the corrected balance.